⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Syringin
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-01 — Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.: Bleomycin-induced pulmonary fibrosis mouse model plus TGF-β1-stimulated fibroblasts: syringin reduced fibroblast senescence markers and lung fibrosis, with ATR/CHK1-p53 axis modulation nominated as the mechanism from a systems-prioritization screen. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Targeting senescence-associated fibrotic signatures identifies syringin as an effective modulator of the ATR/CHK1-p53 axis in idiopathic pulmonary fibrosis.
01-oct-2026
novelty 3
per-area 3
strengthens